. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Clin Genitourin Cancer. 2012 Oct 9;11(2):149–154. doi: 10.1016/j.clgc.2012.09.006

Table 4.

Comparison of EORTC QLQ-C30 Global QOL scores amongst patients in the current study, patients treated with pazopanib in the phase III evaluation of the agent, and patients treated with everolimus in the phase III evaluation of the agent.

Population	N	Score (SD)	P-value
Long-term survivors (current study)	28	73.5 (21.0)	-
Pazopanib
Pazopanib (Baseline)	141	65.8 (20.2)	0.07
Pazopanib (Week 12)	82	67.5 (19.8)	0.18
Pazopanib (Week 24)	49	67.3 (20.7)	0.21
Pazopanib (Week 48)	24	69.4 (19.9)	0.47
Everolimus
Everolimus (Baseline)	224	61.0 (23.1)	0.007